Innovative Pharmaceutical Biotech Limited has issued a profit warning and business update, indicating that the company anticipates a challenging financial outlook. Based on a preliminary review of the unaudited consolidated management accounts for the year ending March 31, 2025, the company expects to record a decline in profits. Several factors contribute to this forecast, including delays in the commercialisation of their Product and a strategic shift in manufacturing plans. Instead of building their own factory, the company has decided to engage external sub-contractors for manufacturing to conserve resources, aligning with their current liquidity position. However, this decision is expected to affect the overall profit margin due to increased costs associated with subcontracting. Shareholders and potential investors are advised to exercise caution and review the upcoming annual results announcement for further details.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.